Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine to Counteract Inflammatory Response in COVID-19 Pneumonia
2020-001258-23Phase 2Completed
- Sponsor
- Azienda Ospedaliero-Universitaria di Parma
- Start
- Apr 2020
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of colchicine in coronavirus disease 2019 (COVID-19) and coronavirus pneumonia (2 arms), sponsored by Azienda Ospedaliero-Universitaria di Parma. Primary endpoint: Time to clinical improvement. Started Apr 2020; status: completed.
02
Drugs
colchicine
03
Conditions
coronavirus disease 2019 (COVID-19)coronavirus pneumonia
Beyond the preview
Go deeper on 2020-001258-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001258-23.